Name: Suzana Giffin, AVP
Company/Organization: Merck & Co., Inc.
Address: 2000 Galloping Hill Rd Kenilworth, NJ 07033
Phone: 908-740-6708
Email: suzana.giffin@merck.com
Date of Request: January 08, 2020
NCCN Guidelines Panel: Bladder Cancer

NCCN Bladder Cancer Panel : On behalf of Merck & Co., Inc., I respectfully request the NCCN Bladder Cancer Panel to review the enclosed information for KEYTRUDA (pembrolizumab), in reference to treatment of patients with non-muscle invasive bladder cancer (NMIBC).

Specific Changes: We respectfully request the NCCN Bladder Cancer Panel to consider updating the NCCN Guidelines to include KEYTRUDA as a treatment option for patients with BCG-unresponsive, high-risk, non-muscle invasive bladder cancer (NMIBC) with carcinoma in-situ (CIS) with or without papillary tumors who are ineligible for or have elected not to undergo cystectomy.

FDA Clearance: KEYTRUDA is approved for the treatment of patients with BCG-unresponsive, high-risk NMIBC with CIS with or without papillary tumors who are ineligible for or have elected not to undergo cystectomy.

Rationale: KEYTRUDA is now approved for the treatment of patients with BCG-unresponsive, high-risk NMIBC with CIS with or without papillary tumors who are ineligible for or have elected not to undergo cystectomy.

The following resources are submitted to assist the committee with their review.

1. KEYTRUDA (pembrolizumab) prescribing information. Merck & Co., Inc.

Thank you for considering this request. Below is my contact information should you need to contact me for additional information.

Sincerely,

Suzana Giffin, AVP
Global Medical Affairs
Merck & Co., Inc.
2000 Galloping Hill Rd
Kenilworth, NJ 07033
908-740-6708
suzana.giffin@merck.com